Business Context and Reporting Period
This Form 8-K was filed by Immudyne, Inc. (not Lifemd, Inc.) on March 26, 2018, reporting a material definitive agreement entered into on that date. The filing details a license agreement between Immudyne PR, LLC (a majority-owned subsidiary) and M.ALPHABET, LLC regarding the "PURPUREX" product line for treating purpura and bruising.
Key Financial Metrics and Terms
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt). Instead, it outlines specific financial obligations and potential equity dilution associated with the new agreement:
- Royalty Rate: 13% of Gross Receipts from Licensed Products.
- Fixed Payments: $50,000 due on the 120-day anniversary and an additional $50,000 on the 360-day anniversary.
- Stock Options (Initial): 100,000 shares at $0.50 per share granted upon execution.
- Stock Options (Performance-Based):
- 100,000 shares at $0.50 if Gross Receipts reach $7.5 million in a calendar year.
- 100,000 shares at $0.50 if Gross Receipts reach $10 million in a calendar year.
- 200,000 shares at $0.75 if Gross Receipts reach $20 million in a calendar year.
Material Changes and Agreements
The primary material change is the entry into an exclusive license agreement for the PURPUREX business. Immudyne PR obtained rights to manufacture, sell, and distribute the products globally, excluding China, Hong Kong, Japan, and Australia. The agreement includes a "Marketing Test Period" of 120 days following the initial marketing campaign, after which Immudyne PR may terminate the agreement at its sole discretion if it chooses not to proceed with sales.
Outlook, Risks, and Contingencies
Management Commentary: The filing indicates a strategic move to expand product offerings through licensing rather than internal development for this specific line.
Risks and Contingencies:
- Termination Rights: Immudyne PR can terminate with 30 days' notice or after the 120-day marketing test period. Either party can terminate for failure to meet Gross Receipt milestones, bankruptcy, or non-payment of royalties.
- Dilution Risk: The agreement creates potential dilution for existing shareholders through the issuance of up to 500,000 shares of common stock based on performance milestones.
- Revenue Dependency: Future profitability depends on the success of the Licensed Products in generating Gross Receipts to cover the 13% royalty and fixed payments.
Investor Verification Checklist
- Verify the exact terms of the "Gross Receipts" definition in the full text of Exhibit 10.1 to understand the royalty base.
- Confirm the current status of the "Marketing Test Period" and whether the company has elected to proceed with commercialization.
- Assess the impact of potential stock option exercises (up to 500,000 shares) on current share count and earnings per share.
- Review the company's cash position to ensure it can meet the upcoming $50,000 milestone payments.
- Clarify the geographic exclusions (China, Hong Kong, Japan, Australia) and their impact on total addressable market.